Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (2): 187-192.doi: 10.19982/j.issn.1000-6621.20210554
• Original Articles • Previous Articles Next Articles
WANG Wei1, YE Yi-nong1, LIN Dong-zi1, ZHONG Qian-hong1, HUANG Fei2, DU Fang-fang3, CHENG Shi-ming3, ZHOU Jie4, ZHANG Xi-lin1(), ZHONG Qiu3(
)
Received:
2021-09-16
Online:
2022-02-10
Published:
2022-02-14
Contact:
ZHANG Xi-lin,ZHONG Qiu
E-mail:zhangxlsn@163.com;zhongqiu@vip.163.com
Supported by:
CLC Number:
WANG Wei, YE Yi-nong, LIN Dong-zi, ZHONG Qian-hong, HUANG Fei, DU Fang-fang, CHENG Shi-ming, ZHOU Jie, ZHANG Xi-lin, ZHONG Qiu. Analysis of epidemiological characteristics of rifampicin resistance tuberculosis in Foshan City, Guangdong Province, 2011-2020[J]. Chinese Journal of Antituberculosis, 2022, 44(2): 187-192. doi: 10.19982/j.issn.1000-6621.20210554
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20210554
年份 | 病原学阳性 | 病原学阴性 | 无病原学结果 | 结核性胸膜炎 | 合计 (例) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
初治患者 (例) | 复治患者 (例) | 小计 (例) | 构成比 (%) | 例数 | 构成比 (%) | 例数 | 构成比 (%) | 例数 | 构成比 (%) | ||
2011 | 1431 | 198 | 1629 | 34.0 | 3009 | 62.8 | 0 | 0.0 | 150 | 3.2 | 4788 |
2012 | 1483 | 226 | 1709 | 34.4 | 3117 | 62.7 | 19 | 0.4 | 128 | 2.5 | 4973 |
2013 | 1437 | 181 | 1618 | 38.5 | 2444 | 58.2 | 10 | 0.2 | 126 | 3.1 | 4198 |
2014 | 1277 | 183 | 1460 | 36.5 | 2395 | 59.9 | 19 | 0.5 | 125 | 3.1 | 3999 |
2015 | 1139 | 156 | 1295 | 33.3 | 2446 | 63.0 | 19 | 0.5 | 124 | 3.2 | 3884 |
2016 | 1137 | 203 | 1340 | 35.6 | 2355 | 62.5 | 1 | 0.0 | 73 | 1.9 | 3769 |
2017 | 1047 | 183 | 1230 | 34.5 | 2235 | 62.6 | 0 | 0.0 | 103 | 2.9 | 3568 |
2018 | 1505 | 170 | 1675 | 52.2 | 1409 | 43.9 | 0 | 0.0 | 126 | 3.9 | 3210 |
2019 | 1526 | 144 | 1670 | 55.6 | 1266 | 42.1 | 0 | 0.0 | 69 | 2.3 | 3005 |
2020 | 1403 | 102 | 1505 | 56.7 | 1081 | 40.7 | 0 | 0.0 | 69 | 2.6 | 2655 |
年份 | 本年登记 | 往年登记 (例) | 合计 (例) | |||||
---|---|---|---|---|---|---|---|---|
初治患者 | 复治患者 | |||||||
登记数(例) | 筛查数(例) | 筛查率(%) | 登记数(例) | 筛查数(例) | 筛查率(%) | |||
2011 | 1431 | 491 | 34.3 | 198 | 86 | 43.4 | 291 | 868 |
2012 | 1483 | 256 | 17.3 | 226 | 93 | 41.2 | 347 | 696 |
2013 | 1437 | 187 | 13.0 | 181 | 136 | 75.1 | 57 | 380 |
2014 | 1277 | 258 | 20.2 | 183 | 140 | 76.5 | 198 | 596 |
2015 | 1139 | 298 | 26.2 | 156 | 131 | 84.0 | 159 | 588 |
2016 | 1137 | 265 | 23.3 | 203 | 188 | 92.6 | 49 | 502 |
2017 | 1047 | 738 | 70.5 | 183 | 182 | 99.5 | 55 | 975 |
2018 | 1505 | 1447 | 96.1 | 170 | 170 | 100.0 | 58 | 1675 |
2019 | 1526 | 1497 | 98.1 | 144 | 144 | 100.0 | 64 | 1705 |
2020 | 1403 | 1403 | 100.0 | 102 | 102 | 100.0 | 55 | 1560 |
年份 | 本年登记 | 往年登记 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
结核分枝 杆菌感染 | 非结核分枝 杆菌感染 | 无结果 | 合计 | 结核分枝 杆菌感染 | 非结核分枝 杆菌感染 | 无结果 | 合计 | ||||||||
例数 | 构成比 (%) | 例数 | 构成比 (%) | 例数 | 构成比 (%) | 例数 | 构成比 (%) | 例数 | 构成比 (%) | 例数 | 构成比 (%) | ||||
2011 | 476 | 82.5 | 11 | 1.9 | 90 | 15.6 | 577 | 238 | 81.8 | 11 | 3.8 | 42 | 14.4 | 291 | |
2012 | 248 | 71.1 | 17 | 4.9 | 84 | 24.0 | 349 | 272 | 78.4 | 7 | 2.0 | 68 | 19.6 | 347 | |
2013 | 192 | 59.4 | 33 | 10.2 | 98 | 30.4 | 323 | 33 | 57.9 | 3 | 5.3 | 21 | 36.8 | 57 | |
2014 | 253 | 63.6 | 25 | 6.3 | 120 | 30.1 | 398 | 119 | 60.1 | 11 | 5.6 | 68 | 34.3 | 198 | |
2015 | 331 | 77.2 | 19 | 4.4 | 79 | 18.4 | 429 | 133 | 83.6 | 4 | 2.5 | 22 | 13.9 | 159 | |
2016 | 349 | 77.0 | 26 | 5.7 | 78 | 17.3 | 453 | 38 | 77.6 | 5 | 10.2 | 6 | 12.2 | 49 | |
2017 | 677 | 73.6 | 28 | 3.0 | 215 | 23.4 | 920 | 45 | 81.8 | 5 | 9.1 | 5 | 9.1 | 55 | |
2018 | 1299 | 80.3 | 44 | 2.7 | 274 | 17.0 | 1617 | 52 | 89.7 | 4 | 6.9 | 2 | 3.4 | 58 | |
2019 | 1120 | 68.3 | 30 | 1.8 | 491 | 29.9 | 1641 | 52 | 81.3 | 6 | 9.4 | 6 | 9.3 | 64 | |
2020 | 1053 | 70.0 | 25 | 1.7 | 427 | 28.3 | 1505 | 45 | 81.8 | 3 | 5.5 | 7 | 12.7 | 55 |
年份 | 本年登记 | 往年登记 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
初治患者 | 复治患者 | |||||||||||||||
检测 例数 | MDR/ RR-PTB | Hr-PTB | 其他 耐药 | 非耐药 | 检测 例数 | MDR/ RR-PTB | Hr-PTB | 其他 耐药 | 非耐药 | 检测 例数 | MDR/ RR-PTB | Hr-PTB | 其他 耐药 | 非耐药 | ||
2011 | 420 | 10(2.4) | 28(6.7) | 339(80.7) | 43(10.2) | 56 | 13(23.2) | 5(8.9) | 31(55.4) | 7(12.5) | 238 | 37(15.5) | 18(7.6) | 163(68.5) | 20(8.4) | |
2012 | 193 | 14(7.3) | 4(2.1) | 157(81.3) | 18(9.3) | 55 | 14(25.5) | 8(14.5) | 32(58.2) | 1(1.8) | 272 | 27(9.9) | 12(4.4) | 217(79.8) | 16(5.9) | |
2013 | 124 | 10(8.1) | 9(7.3) | 101(81.5) | 4(3.1) | 68 | 17(25.0) | 6(8.8) | 44(64.7) | 1(1.5) | 33 | 16(48.5) | 1(3.0) | 15(45.5) | 1(3.0) | |
2014 | 175 | 4(2.3) | 11(6.3) | 151(86.3) | 9(5.1) | 78 | 23(29.5) | 6(7.7) | 43(55.1) | 6(7.7) | 119 | 26(21.8) | 5(4.2) | 83(69.7) | 5(4.3) | |
2015 | 251 | 7(2.8) | 6(2.4) | 219(87.3) | 19(7.5) | 80 | 14(17.5) | 9(11.3) | 50(62.5) | 7(8.8) | 133 | 24(18.0) | 6(4.5) | 88(66.2) | 15(11.3) | |
2016 | 222 | 10(4.5) | 6(2.7) | 181(81.5) | 25(11.3) | 127 | 23(18.1) | 7(5.5) | 90(70.9) | 7(5.5) | 38 | 23(60.5) | 1(2.6) | 10(26.3) | 4(10.6) | |
2017 | 565 | 13(2.3) | 24(4.2) | 484(85.7) | 44(7.8) | 112 | 25(22.3) | 7(6.3) | 68(60.7) | 12(10.7) | 45 | 18(40.0) | 2(4.4) | 23(51.2) | 2(4.4) | |
2018 | 1187 | 9(0.8) | 53(4.5) | 1019(85.8) | 106(8.9) | 112 | 16(14.3) | 4(3.6) | 80(71.4) | 12(10.7) | 52 | 26(50.0) | 1(1.9) | 23(44.2) | 2(3.9) | |
2019 | 1031 | 12(1.2) | 39(3.8) | 924(89.6) | 56(5.4) | 89 | 13(14.6) | 11(12.4) | 62(69.7) | 3(3.3) | 52 | 26(50.0) | 1(1.9) | 25(48.1) | 0(0.0) | |
2020 | 984 | 8(0.8) | 44(4.5) | 877(89.1) | 55(5.6) | 69 | 2(2.9) | 6(8.7) | 55(79.7) | 6(8.7) | 45 | 28(62.2) | 1(2.2) | 16(35.6) | 0(0.0) |
[1] |
Ferri M, Ranucci E, Romagnoli P, et al. Antimicrobial resis-tance: A global emerging threat to public health systems. Crit Rev Food Sci Nutr, 2017, 57(13):2857-2876. doi: 10.1080/10408398.2015.1077192.
doi: 10.1080/10408398.2015.1077192 URL |
[2] |
Singh V, Chibale K. Strategies to Combat Multi-Drug Resis-tance in Tuberculosis. Acc Chem Res, 2021, 54(10):2361-2376. doi: 10.1021/acs.accounts.0c00878.
doi: 10.1021/acs.accounts.0c00878 URL |
[3] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[4] |
Zhao Y, Xu S, Wang L, et al. National survey of drug-resis-tant tuberculosis in China. N Engl J Med, 2012, 366(23):2161-2170. doi: 10.1056/NEJMoa1108789.
doi: 10.1056/NEJMoa1108789 URL |
[5] |
郑惠文, 赵雁林. 中国结核病耐药监测现状与监测体系建设. 中国实用内科杂志, 2015, 35(8):647-650. doi: 10.7504/nk2015070102.
doi: 10.7504/nk2015070102 |
[6] |
马爱静, 赵雁林. 耐药结核病的流行和监测现状. 中国抗生素杂志, 2018, 43(5):502-506. doi: 10.3969/j.issn.1001-8689.2018.05.002.
doi: 10.3969/j.issn.1001-8689.2018.05.002 |
[7] | 国务院办公厅. 国务院办公厅关于印发“十三五”全国结核病防治规划的通知. 国办发〔2017〕16号. 2017-02-06. |
[8] |
吴智龙, 钟倩红, 郭翠弟. 广东省佛山市肺结核患者耐药情况分析. 中国防痨杂志, 2016, 38(7):597-600. doi: 10.3969/j.issn.1000-6621.2016.07.017.
doi: 10.3969/j.issn.1000-6621.2016.07.017 |
[9] |
Nguyen L. Antibiotic resistance mechanisms in M.tuberculosis: an update. Arch Toxicol, 2016, 90(7):1585-1604. doi: 10.1007/s00204-016-1727-6.
doi: 10.1007/s00204-016-1727-6 pmid: 27161440 |
[10] |
Chien JY, Chen YT, Wu SG, et al. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect, 2015, 21(1):59-68. doi: 10.1016/j.cmi.2014.08.008.
doi: 10.1016/j.cmi.2014.08.008 URL |
[11] |
Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res, 2020, 152(3):185-226. doi: 10.4103/ijmr.IJMR_902_20.
doi: 10.4103/ijmr.IJMR_902_20 URL |
[12] |
洪创跃, 李金莉, 赵广录, 等. 2013—2017年深圳市非结核分枝杆菌流行状况分析. 中国防痨杂志, 2019, 41(5):529-533. doi: 10.3969/j.issn.1000-6621.2019.05.011.
doi: 10.3969/j.issn.1000-6621.2019.05.011 |
[13] |
王春花, 孙蕊, 王志锐, 等. 2011—2015年天津地区非结核分枝杆菌感染趋势及耐药情况分析. 中国防痨杂志, 2017, 39(11):1250-1253. doi: 10.3969/j.issn.1000-6621.2017.11.020.
doi: 10.3969/j.issn.1000-6621.2017.11.020 |
[14] |
Kontturi A, Soini H, Ollgren J, et al. Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016. Clin Infect Dis, 2018, 67(8):1256-1261. doi: 10.1093/cid/ciy241.
doi: 10.1093/cid/ciy241 pmid: 29584893 |
[15] |
Gopalaswamy R, Shanmugam S, Mondal R, et al. Of tuberculosis and non-tuberculous mycobacterial infections-a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci, 2020, 27(1):74. doi: 10.1186/s12929-020-00667-6.
doi: 10.1186/s12929-020-00667-6 pmid: 32552732 |
[16] |
Suthar AB, Moonan PK, Alexander HL. Towards national systems for continuous surveillance of antimicrobial resistance: Lessons from tuberculosis. PLoS Med, 2018, 15(9):e1002658. doi: 10.1371/journal.pmed.1002658.
doi: 10.1371/journal.pmed.1002658 URL |
[17] |
Ruan YZ, Li L, Lin X, et al. Practical Experiences of Delivering Multidrug-Resistant Tuberculosis Comprehensive Supportive Care Services in China. China CDC Weekly, 2021, 3(26):566-568. doi: 10.46234/ccdcw2021.146.
doi: 10.46234/ccdcw2021.146 URL |
[18] |
杨婷婷, 高谦. 构建基于全基因组数据的结核病耐药及传播监测网络. 中国防痨杂志, 2021, 43(7):645-648. doi: 10.3969/j.issn.1000-6621.2021.07.001.
doi: 10.3969/j.issn.1000-6621.2021.07.001 |
[19] |
张洁, 任怡宣, 潘丽萍, 等. 全基因组测序在结核分枝杆菌研究中的应用. 中国防痨杂志, 2020, 42(7):737-740. doi: 10.3969/j.issn.1000-6621.2020.07.017.
doi: 10.3969/j.issn.1000-6621.2020.07.017 |
[20] |
中国防痨协会. 结核病领域研究进展(2020年度). 中国防痨杂志, 2021, 43(1):6-11. doi: 10.3969/j.issn.1000-6621.2021.01.003.
doi: 10.3969/j.issn.1000-6621.2021.01.003 |
[1] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[2] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[3] | Yang Ziyi, Chen Suting. Research progress on bedaquiline resistance and drug resistance diagnosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 374-379. |
[4] | Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168. |
[5] | Xu Zian, Pu Feifei, Feng Jing, Xia Ping. Research progress of high-throughput sequencing technology in the diagnosis and treatment of osteoarticular tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 224-230. |
[6] | Liang Linlong, Pei Yi, Zhou Haiyi, Xie Qifang, Zhang Feng, Jiang Jie, Liu Fuqiang. The epidemiological characteristics and trends of tuberculosis among children aged 0-14 years in Hunan Province from 2014 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 29-35. |
[7] | Geng Zimei, Wang Chaohong, Long Sibo, Zheng Maike, Shi Yiheng, Sun Yong, Zhao Yan, Wang Guirong. Analysis of bacteriological positivity and rifampicin resistance in patients with severe pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1050-1055. |
[8] | Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076. |
[9] | Yang Liangzi, Zhang Peize, Lu Shuihua. Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876. |
[10] | Xue Yi, Liang Qian, Qi Haoran, Liang Ruixia, Huang Hairong. Reliability analysis of rifampicin-resistance detected by different diagnostics as a predictor for multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 892-896. |
[11] | Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei. Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950. |
[12] | Gao Lei, Liang Yaxue, Liu Shengsheng, Wang Hua. Analysis of treatment outcomes and influencing factors in 144 elderly patients with rifampicin drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 799-807. |
[13] | Zhang Hongtai, Ren Yixuan, Hu peilei, Wang Nenhan, Li Jie, Tian Lili, Zhao Yanfeng, Chen Shuangshuang, Li Chuanyou. Comparison of microbiota diversity in the sputum of pulmonary tuberculosis patients with rifampicin resistance or sensitivity [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 625-633. |
[14] | Lei Hui, Zhang Shu, Li Ting, Gao Yuan, Liu Shuang, Chen Chuang, Xia Lan, Wang Weina, Gao Wenfeng, He Jinge. Analysis of infection patterns and drug resistance of 22 recurrent pulmonary tuberculosis patients in Sichuan based on whole-genome sequencing [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 641-647. |
[15] | Du Yuhua, Feng Yajuan, Lei Yu, Lai Keng, He Weiyun. Analysis of the detection and treatment of rifampicin-resistant pulmonary tuberculosis patients in Guangzhou during the “12th Five-Year Plan” and “13th Five-Year Plan” periods [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 678-686. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||